Cargando…
Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers
The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) has been tasked by the World Health Organization (WHO) to review the extent to which animal-based testing methods are described in their manuals, guidelines and recommendations for vaccines and bioth...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109345/ https://www.ncbi.nlm.nih.gov/pubmed/36376163 http://dx.doi.org/10.1016/j.biologicals.2022.11.002 |
_version_ | 1785027044747247616 |
---|---|
author | Lilley, Elliot Coppens, Emmanuelle Das, Pradip Galaway, Francis Isbrucker, Richard Sheridan, Sarah Stickings, Paul Holmes, Anthony |
author_facet | Lilley, Elliot Coppens, Emmanuelle Das, Pradip Galaway, Francis Isbrucker, Richard Sheridan, Sarah Stickings, Paul Holmes, Anthony |
author_sort | Lilley, Elliot |
collection | PubMed |
description | The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) has been tasked by the World Health Organization (WHO) to review the extent to which animal-based testing methods are described in their manuals, guidelines and recommendations for vaccines and biotherapeutics. The aim is to identify and recommend where updates to these documents can lead to an increased and more harmonised adoption of 3Rs principles (i.e. Replacement, Reduction and Refinement of animal tests) in the quality control and batch release testing requirements for vaccines and biotherapeutics. Developing recommendations that are widely applicable by both the manufacturers and national regulatory authorities for vaccines and biologicals globally requires a detailed understanding of how different organisations view the opportunities and barriers to better integration of the 3Rs. To facilitate this, we developed and distributed a survey aimed at vaccine and biotherapeutics manufacturers in July 2021. In this paper, we present the key findings from this survey and how these will help inform the recommendations for wider integration of 3Rs approaches by WHO in their guidance documents applicable to the quality control and batch testing of vaccines and biotherapeutics. |
format | Online Article Text |
id | pubmed-10109345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Academic Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101093452023-04-18 Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers Lilley, Elliot Coppens, Emmanuelle Das, Pradip Galaway, Francis Isbrucker, Richard Sheridan, Sarah Stickings, Paul Holmes, Anthony Biologicals Article The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) has been tasked by the World Health Organization (WHO) to review the extent to which animal-based testing methods are described in their manuals, guidelines and recommendations for vaccines and biotherapeutics. The aim is to identify and recommend where updates to these documents can lead to an increased and more harmonised adoption of 3Rs principles (i.e. Replacement, Reduction and Refinement of animal tests) in the quality control and batch release testing requirements for vaccines and biotherapeutics. Developing recommendations that are widely applicable by both the manufacturers and national regulatory authorities for vaccines and biologicals globally requires a detailed understanding of how different organisations view the opportunities and barriers to better integration of the 3Rs. To facilitate this, we developed and distributed a survey aimed at vaccine and biotherapeutics manufacturers in July 2021. In this paper, we present the key findings from this survey and how these will help inform the recommendations for wider integration of 3Rs approaches by WHO in their guidance documents applicable to the quality control and batch testing of vaccines and biotherapeutics. Academic Press 2023-02 /pmc/articles/PMC10109345/ /pubmed/36376163 http://dx.doi.org/10.1016/j.biologicals.2022.11.002 Text en . https://creativecommons.org/licenses/by/3.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Lilley, Elliot Coppens, Emmanuelle Das, Pradip Galaway, Francis Isbrucker, Richard Sheridan, Sarah Stickings, Paul Holmes, Anthony Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers |
title | Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers |
title_full | Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers |
title_fullStr | Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers |
title_full_unstemmed | Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers |
title_short | Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers |
title_sort | integrating 3rs approaches in who guidelines for the batch release testing of biologicals: responses from a survey of vaccines and biological therapeutics manufacturers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109345/ https://www.ncbi.nlm.nih.gov/pubmed/36376163 http://dx.doi.org/10.1016/j.biologicals.2022.11.002 |
work_keys_str_mv | AT lilleyelliot integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers AT coppensemmanuelle integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers AT daspradip integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers AT galawayfrancis integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers AT isbruckerrichard integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers AT sheridansarah integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers AT stickingspaul integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers AT holmesanthony integrating3rsapproachesinwhoguidelinesforthebatchreleasetestingofbiologicalsresponsesfromasurveyofvaccinesandbiologicaltherapeuticsmanufacturers |